Zhao Jing-Lin, Yang Yue-Jin, Cui Chuan-Jue, You Shi-Jie, Wu Yong-Jian, Gao Run-Lin
Department of Cardiology, Cardiovascular Institute and Fu-Wai Heart Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Bei Li Shi Road 167, Xi-Cheng District, Beijing 100037, China.
Cardiovasc Drugs Ther. 2006 Jun;20(3):167-75. doi: 10.1007/s10557-006-8284-9.
Adenosine and calcium channel blockers have been used in the treatment of angiographic no-reflow directly after angioplasty for acute myocardial infarction (AMI). However, their effects on tissue perfusion after AMI and reperfusion are undefined. The present study was designed to compare the effect of adenosine with that of the calcium channel blockers diltiazem and verapamil on myocardial no-reflow.
Coronary ligation area and area of no-reflow were determined with both myocardial contrast echocardiography in vivo and histopathological evaluation in 44 Yorkshire mini-swines randomized into five study groups: ten in control, eight in adenosine-treated, nine in diltiazem-treated, nine in verapamil-treated and eight in sham-operated. An acute myocardial infarction and reperfusion model was created with 3-h occlusion of the left anterior descending coronary artery followed by 1-h reperfusion.
Compared with the control group, adenosine significantly decreased the area of no-reflow measured with both methods from 78.5 and 82.3% to 20.7 and 21.5% of ligation area, respectively (both P < 0.01), reduced necrosis area, maintained VE-cadherin, beta-catenin and gamma-catenin levels in reflow myocardium (P < 0.05-0.01). Although diltiazem and verapamil also significantly decreased the area of no-reflow, they failed to significantly modify necrosis area, VE-cadherin, beta-catenin and gamma-catenin levels.
These findings support the concept that adenosine can reduce both structural and functional no-reflow, while calcium channel blockade can only reduce functional no-reflow.
腺苷和钙通道阻滞剂已被用于急性心肌梗死(AMI)血管成形术后直接治疗血管造影无复流。然而,它们对AMI和再灌注后组织灌注的影响尚不清楚。本研究旨在比较腺苷与钙通道阻滞剂地尔硫卓和维拉帕米对心肌无复流的影响。
采用体内心肌对比超声心动图和组织病理学评估,在44只约克郡小型猪中确定冠状动脉结扎区域和无复流区域,这些猪被随机分为五个研究组:对照组10只,腺苷治疗组8只,地尔硫卓治疗组9只,维拉帕米治疗组9只,假手术组8只。通过结扎左前降支冠状动脉3小时,然后再灌注1小时,建立急性心肌梗死和再灌注模型。
与对照组相比,腺苷显著降低了两种方法测量的无复流面积,分别从结扎面积的78.5%和82.3%降至20.7%和21.5%(均P < 0.01),减少了坏死面积,维持了再流心肌中VE-钙黏蛋白、β-连环蛋白和γ-连环蛋白水平(P < 0.05 - 0.01)。虽然地尔硫卓和维拉帕米也显著降低了无复流面积,但它们未能显著改变坏死面积、VE-钙黏蛋白、β-连环蛋白和γ-连环蛋白水平。
这些发现支持了腺苷可减少结构性和功能性无复流,而钙通道阻滞剂只能减少功能性无复流的观点。